| NCT04060147 |
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis |
https://ClinicalTrials.gov/show/NCT04060147 |
Recruiting |
Gilead Sciences |
2021-06-30 |
| NCT03710122 |
Vancomycin for Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT03710122 |
Recruiting |
Mayo Clinic |
2022-05-31 |
| NCT03359174 |
An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT03359174 |
Recruiting |
Yale University |
2020-12-01 |
| NCT03333928 |
A POC and Dose-Ranging Study of HTD1801 in PSC Patients |
https://ClinicalTrials.gov/show/NCT03333928 |
Active, not recruiting |
HighTide Biopharma Pty Ltd |
2020-04-30 |
| NCT03183570 |
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis and Primary Sclerosing Cholangitis Using PET/CT |
https://ClinicalTrials.gov/show/NCT03183570 |
Recruiting |
Stanford University |
2021-04-14 |
| NCT03124108 |
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid |
https://ClinicalTrials.gov/show/NCT03124108 |
Completed |
Genfit |
2018-10-31 |
| NCT03112681 |
Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis |
https://ClinicalTrials.gov/show/NCT03112681 |
Active, not recruiting |
Zydus Discovery DMCC |
2020-08-31 |
| NCT03104582 |
Best Biliary Drainage Option in Advanced Klatskin Tumor |
https://ClinicalTrials.gov/show/NCT03104582 |
Completed |
Hepatopancreatobiliary Surgery Institute of Gansu Province |
2017-07-14 |
| NCT03104569 |
Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma |
https://ClinicalTrials.gov/show/NCT03104569 |
Recruiting |
Hepatopancreatobiliary Surgery Institute of Gansu Province |
2021-04-01 |
| NCT03087656 |
Antibiotics to Decrease Post ERCP Cholangitis |
https://ClinicalTrials.gov/show/NCT03087656 |
Recruiting |
University of Southern California |
2021-02-23 |
| NCT03069976 |
“Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Identification With Antibiotics in Children” |
https://ClinicalTrials.gov/show/NCT03069976 |
Recruiting |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2020-12-31 |
| NCT02997878 |
A Single-arm,Phase IIa,Safety and Efficacy Trial of Selected MSCs in the Treatment of Patients With PSC & AiH |
https://ClinicalTrials.gov/show/NCT02997878 |
Recruiting |
University of Birmingham |
2021-12-31 |
| NCT02978339 |
A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC) |
https://ClinicalTrials.gov/show/NCT02978339 |
Completed |
Mayo Clinic |
2018-11-16 |
| NCT02967926 |
Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy |
https://ClinicalTrials.gov/show/NCT02967926 |
Completed |
Chulalongkorn University |
2016-10-31 |
| NCT02966834 |
Dose Response Study of GSK2330672 for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis |
https://ClinicalTrials.gov/show/NCT02966834 |
Completed |
GlaxoSmithKline |
2020-04-15 |
| NCT02943460 |
Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis |
https://ClinicalTrials.gov/show/NCT02943460 |
Completed |
Gilead Sciences |
2018-02-28 |
| NCT02943447 |
Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis |
https://ClinicalTrials.gov/show/NCT02943447 |
Completed |
Gilead Sciences |
2018-07-27 |
| NCT02936596 |
Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome |
https://ClinicalTrials.gov/show/NCT02936596 |
Recruiting |
West China Hospital |
2020-06-01 |
| NCT02884557 |
NKT Role in the Regulation of the Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT02884557 |
Recruiting |
University Hospital, Lille |
2021-09-30 |
| NCT02797665 |
Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids |
https://ClinicalTrials.gov/show/NCT02797665 |
Active, not recruiting |
Peking Union Medical College Hospital |
2019-04-30 |
| NCT02712736 |
Quality of Life in Patients With Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT02712736 |
Completed |
Duke University |
2018-09-22 |
| NCT02704364 |
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT02704364 |
Completed |
NGM Biopharmaceuticals, Inc |
2017-06-30 |
| NCT02653625 |
PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT02653625 |
Completed |
Tobira Therapeutics, Inc. |
2017-08-31 |
| NCT02594891 |
Effect of 8.5 F Plastic Stent Without Proximal Flap on Prevention of Post-ERCP Cholangitis |
https://ClinicalTrials.gov/show/NCT02594891 |
Completed |
First People’s Hospital of Hangzhou |
2016-02-29 |
| NCT01824186 |
Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy |
https://ClinicalTrials.gov/show/NCT01824186 |
Completed |
National University Hospital, Singapore |
2012-10-31 |
| NCT02516605 |
A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients |
https://ClinicalTrials.gov/show/NCT02516605 |
Completed |
Novartis |
2018-08-02 |
| NCT02464020 |
A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT02464020 |
Completed |
University of Minnesota |
2017-05-01 |
| NCT02446665 |
Disease Status in Primary Sclerosing Cholangitis by Elastography |
https://ClinicalTrials.gov/show/NCT02446665 |
Active, not recruiting |
University Health Network, Toronto |
2019-12-31 |
| NCT02424175 |
Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. |
https://ClinicalTrials.gov/show/NCT02424175 |
Completed |
Brigham and Women’s Hospital |
2017-08-30 |
| NCT02308111 |
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis |
https://ClinicalTrials.gov/show/NCT02308111 |
Recruiting |
Intercept Pharmaceuticals |
2024-12-31 |
| NCT02239211 |
A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT02239211 |
Completed |
University of Birmingham |
2018-10-23 |
| NCT02177136 |
Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) |
https://ClinicalTrials.gov/show/NCT02177136 |
Completed |
Intercept Pharmaceuticals |
2017-03-07 |
| NCT02137668 |
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin |
https://ClinicalTrials.gov/show/NCT02137668 |
Recruiting |
Sacramento Pediatric Gastroenterology |
2018-05-31 |
| NCT02098486 |
Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP |
https://ClinicalTrials.gov/show/NCT02098486 |
Completed |
Kangbuk Samsung Hospital |
2015-09-30 |
| NCT02070627 |
Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy – Use in Acute Cholecystitis Sub-Study |
https://ClinicalTrials.gov/show/NCT02070627 |
Completed |
Ohio State University |
2014-08-31 |
| NCT02061540 |
Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT02061540 |
Completed |
Mirum Pharmaceuticals, Inc. |
2016-02-29 |
| NCT01988506 |
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases |
https://ClinicalTrials.gov/show/NCT01988506 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2020-08-13 |
| NCT01879735 |
Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT |
https://ClinicalTrials.gov/show/NCT01879735 |
Completed |
University of Aarhus |
2014-09-30 |
| NCT01802073 |
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects |
https://ClinicalTrials.gov/show/NCT01802073 |
Completed |
Stanford University |
2015-08-31 |
| NCT01755507 |
Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT01755507 |
Completed |
Dr. Falk Pharma GmbH |
2015-10-31 |
| NCT01744847 |
DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study |
https://ClinicalTrials.gov/show/NCT01744847 |
Completed |
Soon Chun Hyang University |
2012-08-31 |
| NCT01695174 |
A Pilot Study of Xifaxan to Treat Patients With PSC |
https://ClinicalTrials.gov/show/NCT01695174 |
Completed |
Mayo Clinic |
2013-12-31 |
| NCT01672853 |
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) |
https://ClinicalTrials.gov/show/NCT01672853 |
Completed |
Gilead Sciences |
2016-08-08 |
| NCT01456468 |
Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT01456468 |
Completed |
Yale University |
2014-06-30 |
| NCT01322386 |
Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin |
https://ClinicalTrials.gov/show/NCT01322386 |
Completed |
Stanford University |
2010-10-31 |
| NCT04047160 |
Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I) |
https://ClinicalTrials.gov/show/NCT04047160 |
Recruiting |
Komagome Hospital |
2021-03-31 |
| NCT04037007 |
Efficacy of Fistulotomy for Biliary Cannulation |
https://ClinicalTrials.gov/show/NCT04037007 |
Recruiting |
Coordinación de Investigación en Salud, Mexico |
2020-03-03 |
| NCT04006886 |
Gluten-free Diet in Patients With Primary Sclerosing Cholangitis (PSC) |
https://ClinicalTrials.gov/show/NCT04006886 |
Completed |
Universitätsklinikum Hamburg-Eppendorf |
2019-05-09 |
| NCT03995212 |
Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus |
https://ClinicalTrials.gov/show/NCT03995212 |
Recruiting |
Cara Therapeutics, Inc. |
2021-01-31 |
| NCT03890120 |
Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT03890120 |
Recruiting |
Gilead Sciences |
2023-01-31 |
| NCT03852836 |
Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images |
https://ClinicalTrials.gov/show/NCT03852836 |
Recruiting |
IHU Strasbourg |
2021-02-28 |
| NCT03754491 |
The Comparisons of One-stage Stone Removal in Mild and Moderate Cholangitis |
https://ClinicalTrials.gov/show/NCT03754491 |
Recruiting |
Chang Gung Memorial Hospital |
2020-05-31 |
| NCT03742973 |
A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA |
https://ClinicalTrials.gov/show/NCT03742973 |
Completed |
Eli Lilly and Company |
2019-09-26 |
| NCT03722576 |
Vidofludimus Calcium for Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT03722576 |
Recruiting |
Mayo Clinic |
2020-10-31 |
| NCT03716232 |
Kaffes Stent in the Management of Post-surgical Biliary Strictures |
https://ClinicalTrials.gov/show/NCT03716232 |
Recruiting |
Cairo University |
2020-07-31 |
| NCT03668145 |
Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis |
https://ClinicalTrials.gov/show/NCT03668145 |
Recruiting |
Xijing Hospital of Digestive Diseases |
2019-12-31 |
| NCT03665519 |
Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis |
https://ClinicalTrials.gov/show/NCT03665519 |
Active, not recruiting |
National Scientific Medical Center, Kazakhstan |
2020-09-30 |
| NCT03561584 |
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT03561584 |
Recruiting |
Brigham and Women’s Hospital |
2020-07-01 |
| NCT03516006 |
Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT03516006 |
Active, not recruiting |
Fuzhou General Hospital |
2019-01-31 |
| NCT03422042 |
Short Duration Versus Fourteen Days Antibiotic in Common Bile Duct Cholangitis |
https://ClinicalTrials.gov/show/NCT03422042 |
Completed |
Prince of Songkla University |
2019-02-20 |
| NCT01148693 |
Gentamicin in Preventing Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Cholangitis in Non-calculus Stenting |
https://ClinicalTrials.gov/show/NCT01148693 |
Completed |
Tehran University of Medical Sciences |
2010-12-31 |
| NCT01088607 |
Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT01088607 |
Completed |
University of Tennessee |
2016-12-31 |
| NCT01085760 |
A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT01085760 |
Completed |
Mayo Clinic |
2011-11-30 |
| NCT00955149 |
Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) |
https://ClinicalTrials.gov/show/NCT00955149 |
Completed |
Mayo Clinic |
2013-04-30 |
| NCT03394924 |
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis |
https://ClinicalTrials.gov/show/NCT03394924 |
Completed |
Enanta Pharmaceuticals |
2019-12-19 |
| NCT03226067 |
Study to Assess Safety and Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. |
https://ClinicalTrials.gov/show/NCT03226067 |
Completed |
Genkyotex SA |
2019-04-11 |
| NCT03099603 |
A Study of HTD1801 in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT03099603 |
Completed |
HighTide Biopharma Pty Ltd |
2017-07-11 |
| NCT02705638 |
Treatment of IgG4-Related Disease With Revlimid and Rituximab |
https://ClinicalTrials.gov/show/NCT02705638 |
Completed |
Mayo Clinic |
2019-04-30 |
| NCT03872921 |
norUrsodeoxycholic Acid vs Placebo in PSC |
https://ClinicalTrials.gov/show/NCT03872921 |
Recruiting |
Dr. Falk Pharma GmbH |
2021-04-30 |
| NCT00630942 |
Minocycline in Primary Sclerosing Cholangitis (PSC) |
https://ClinicalTrials.gov/show/NCT00630942 |
Completed |
Mayo Clinic |
2007-05-31 |
| NCT00591968 |
Telesonography Adaptation and Use to Improve the Standard of Patient Care Within a Dominican Community |
https://ClinicalTrials.gov/show/NCT00591968 |
Completed |
Edward Via Virginia College of Osteopathic Medicine |
2008-03-31 |
| NCT00325013 |
Evaluation of DHA for the Treatment of PSC |
https://ClinicalTrials.gov/show/NCT00325013 |
Completed |
Beth Israel Deaconess Medical Center |
2012-05-31 |
| NCT00166868 |
Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy |
https://ClinicalTrials.gov/show/NCT00166868 |
Completed |
National Taiwan University Hospital |
2012-01-31 |
| NCT00059202 |
Trial of High-dose Urso in Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT00059202 |
Completed |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
NA |
| NCT00004762 |
Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT00004762 |
Completed |
Office of Rare Diseases (ORD) |
NA |
| NCT00004842 |
Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis |
https://ClinicalTrials.gov/show/NCT00004842 |
Completed |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
1999-04-30 |